Latest & greatest articles for adalimumab

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adalimumab or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adalimumab and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for adalimumab

41. Adalimumab (Humira) - for the treatment of moderately to severely active Crohn's disease in paediatric patients

Adalimumab (Humira) - for the treatment of moderately to severely active Crohn's disease in paediatric patients %PDF-1.5 %���� 1 0 obj >>> endobj 2 0 obj > endobj 3 0 obj >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��[[oܶ~7������,^%��\N�'E�'Id�l�9�K�]��S��gfHJ�V\o�-ot!����73�(:����ۗ�������ū�ї��g����I�%1�yΣ3'YT.NO�]7��^��?NO��}�?�7��� ��MQ�V�����j����ú:W�̗�f�Zڑ^\��,b,Ndty}z�hPey�ã4ױ

All Wales Medicines Strategy Group2017

42. HUMIRA (adalimumab), anti-TNF-? immunosuppressant

HUMIRA (adalimumab), anti-TNF-? immunosuppressant Haute Autorité de Santé - HUMIRA (adalimumab), immunossuppresseur anti-TNFα Contribuer à la régulation par la qualité et l'efficience Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments HUMIRA (adalimumab), immunossuppresseur anti-TNFα Substance active (DCI) adalimumab OPHTALMOLOGIE - Nouvelle indication Nature de la demande Extension d'indication Avis de la CT du

Haute Autorite de sante2017

43. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study.

Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. BACKGROUND: To date, head-to-head trials comparing the efficacy and safety of biological disease-modifying antirheumatic drugs within the same class, including TNF inhibitors, in patients with active rheumatoid arthritis despite methotrexate therapy are lacking. We aimed to compare the efficacy and safety of two different TNF (...) by the 2010 ACR/EULAR criteria, and had prognostic factors for severe disease progression, including a positive rheumatoid factor, or anti-cyclic citrullinated peptide antibody result, or both. Participants were randomly assigned (1:1) via an interactive voice and web response system with no stratification to receive certolizumab pegol plus methotrexate or adalimumab plus methotrexate. All study staff were kept masked throughout the study and participants were masked until week 12. At week 12, patients

Lancet2016

44. Adalimumab (Humira) - Treatment of non-infectious intermediate, posterior and panuveitis in adult patients

Adalimumab (Humira) - Treatment of non-infectious intermediate, posterior and panuveitis in adult patients Published 07 November 2016 Statement of Advice: adalimumab (Humira ® ) 40mg/0.4ml Pre-filled Syringe and Pre-filled Pen adalimumab (Humira ® ) 40mg/0.8ml Pre-filled Syringe and Pre-filled Pen (No: 1209/16) AbbVie Limited 07 October 2016 ADVICE: in the absence of a submission from the holder of the marketing authorisation adalimumab (Humira ® ) is not recommended for use within NHS Scotland (...) ) is currently undertaking a multiple technology appraisal (MTA) that includes the use of adalimumab in this indication. However, due to the significant time interval between product availability and the expected date of NICE guidance, not recommended advice has been issued. Advice context: No part of this advice may be used without the whole of the advice being quoted in full. This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug

Scottish Medicines Consortium2016

45. Adalimumab (Humira) - Treatment of moderately active Crohn's disease in paediatric patients

Adalimumab (Humira) - Treatment of moderately active Crohn's disease in paediatric patients Published 07 November 2016 Statement of Advice: adalimumab (Humira ® ) 40mg/0.4ml Pre-filled Syringe and Pre-filled Pen adalimumab (Humira ® ) 40mg/0.8ml Pre-filled Syringe and Pre-filled Pen adalimumab (Humira ® ) 40mg/0.8ml vial for paediatric use (No: 1208/16) AbbVie Limited 07 October 2016 ADVICE: in the absence of a submission from the holder of the marketing authorisation adalimumab (Humira (...) cannot recommend its use within NHSScotland. SMC has previously accepted adalimumab for restricted use for the treatment of severe active Crohn's disease in paediatric patients (6 to 17 years of age) who have had an inadequate response to conventional therapy including primary nutrition therapy, a corticosteroid, and an immunomodulator, or who are intolerant to or have contraindications for such therapies (SMC 880/13). This advice remains valid. Advice context: No part of this advice may be used

Scottish Medicines Consortium2016

46. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab

Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab 27670599 2016 09 27 2017 02 20 1572-0241 111 12 2016 Dec The American journal of gastroenterology Am. J. Gastroenterol. Crohn's Disease Activity and Concomitant Immunosuppressants Affect the Risk of Serious and Opportunistic Infections in Patients Treated With Adalimumab. 1806-1815 10.1038/ajg.2016.433 Anti-tumor necrosis factor (TNF) drugs (...) are commonly used to treat moderate-to-severe Crohn's disease (CD). Both the activity of CD and the concomitant immunosuppressants (corticosteroids and immunomodulators) used with anti-TNF drugs could increase the risk of infection. We determined the relative risk of serious and opportunistic infections associated with increasing disease activity and concomitant immunomodulators and corticosteroids in patients with CD treated with adalimumab. This pooled analysis identified incident treatment-emergent

EvidenceUpdates2016

47. Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis.

Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis. 27747583 2016 10 17 2017 04 10 2198-6576 3 2 2016 Dec Rheumatology and therapy Rheumatol Ther Randomized Crossover Comparison of Injection Site Pain with 40 mg/0.4 or 0.8 mL Formulations of Adalimumab in Patients with Rheumatoid Arthritis. 257-270 Adalimumab, an anti-tumor necrosis factor antibody, is currently available in a 40 mg/0.8 mL formulation (...) . The objective of this analysis was to evaluate injection site-related pain, safety, and tolerability of a 40 mg/0.4 mL formulation of adalimumab that had fewer excipients, a smaller volume, and a delivery presentation with a smaller gauge needle, versus the current 40 mg/0.8 mL formulation in patients with rheumatoid arthritis (RA). Two identically designed, phase 2, randomized, single-blind, two-period crossover studies were conducted in Belgium and the Czech Republic (Study 1) and Australia, Canada

Rheumatology and therapy2016 Full Text: Link to full Text with Trip Pro

48. Adalimumab in Patients with Active Noninfectious Uveitis.

Adalimumab in Patients with Active Noninfectious Uveitis. BACKGROUND: Patients with noninfectious uveitis are at risk for long-term complications of uncontrolled inflammation, as well as for the adverse effects of long-term glucocorticoid therapy. We conducted a trial to assess the efficacy and safety of adalimumab as a glucocorticoid-sparing agent for the treatment of noninfectious uveitis. METHODS: This multinational phase 3 trial involved adults who had active noninfectious intermediate (...) uveitis, posterior uveitis, or panuveitis despite having received prednisone treatment for 2 or more weeks. Investigators and patients were unaware of the study-group assignments. Patients were randomly assigned in a 1:1 ratio to receive adalimumab (a loading dose of 80 mg followed by a dose of 40 mg every 2 weeks) or matched placebo. All patients received a mandatory prednisone burst followed by tapering of prednisone over the course of 15 weeks. The primary efficacy end point was the time

NEJM2016

49. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of t

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of t 27553214 2016 09 07 2017 04 10 1468-2060 76 1 2017 Jan Annals of the rheumatic diseases Ann. Rheum. Dis. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis (...) : results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1. 79-87 10.1136/annrheumdis-2016-209709 To assess the safety and efficacy of ixekizumab, a monoclonal antibody that inhibits interleukin-17A, in a double-blind phase III trial enrolling patients with active psoriatic arthritis (PsA). Patients naive to biologic therapy with active PsA were randomised to subcutaneous injections of placebo (N=106), adalimumab 40

EvidenceUpdates2016

50. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial

Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial 27307526 2016 08 02 2016 08 02 0315-162X 43 8 2016 Aug The Journal of rheumatology J. Rheumatol. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial. 1480-9 10.3899/jrheum.151009 To examine the clinical and ultrasonographic (US) outcomes of reducing (...) methotrexate (MTX) dosage upon initiating adalimumab (ADA) in MTX-inadequate responders with moderately to severely active rheumatoid arthritis (RA). MUSICA (NCT01185288) was a double-blind, randomized, parallel-arm study of 309 patients with RA receiving MTX ≥ 15 mg/week for ≥ 12 weeks before screening. Patients were randomized to high dosage (20 mg/week) or low dosage (7.5 mg/week) MTX; all patients received 40 mg open-label ADA every other week for 24 weeks. The primary endpoint was Week 24 mean 28

EvidenceUpdates2016

51. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial.

Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. BACKGROUND: Non-infectious uveitis is a potentially sight-threatening ocular disorder caused by chronic inflammation and its complications. Therapeutic success is limited by systemic adverse effects associated with long-term corticosteroid and immunomodulator use if topical medication (...) is not sufficient to control the inflammation. We aimed to assess the efficacy and safety of adalimumab in patients with inactive, non-infectious uveitis controlled by systemic corticosteroids. METHODS: We did this multicentre, double-masked, randomised, placebo-controlled phase 3 trial at 62 study sites in 21 countries in the USA, Canada, Europe, Israel, Australia, and Latin America. Patients (aged ≥18 years) with inactive, non-infectious intermediate, posterior, or panuveitic uveitis controlled by 10-35 mg

Lancet2016

52. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.

Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa. BACKGROUND: Hidradenitis suppurativa is a painful, chronic inflammatory skin disease with few options for effective treatment. In a phase 2 trial, adalimumab, an antibody against tumor necrosis factor α, showed efficacy against hidradenitis suppurativa. METHODS: PIONEER I and II were similarly designed, phase 3 multicenter trials of adalimumab for hidradenitis suppurativa, with two double-blind, placebo-controlled periods. In period (...) 1, patients were randomly assigned in a 1:1 ratio to 40 mg of adalimumab weekly or matching placebo for 12 weeks. In period 2, patients were reassigned to adalimumab at a weekly or every-other-week dose or to placebo for 24 weeks. The primary end point was a clinical response, defined as at least a 50% reduction from baseline in the abscess and inflammatory-nodule count, with no increase in abscess or draining-fistula counts, at week 12. RESULTS: We enrolled 307 patients in PIONEER I and 326

NEJM2016

53. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis

Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis 27338778 2016 06 24 2017 04 10 1468-2060 76 2 2017 Feb Annals of the rheumatic diseases Ann. Rheum. Dis. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. 414-417 10.1136/annrheumdis-2016-209322 Adalimumab has been used in patients with moderately to severely active rheumatoid arthritis (RA) for over (...) 10 years and has a well-established safety profile across multiple indications. To update adverse events (AEs) of special interest from global adalimumab clinical trials in patients with RA. This analysis includes 15 132 patients exposed to adalimumab in global RA clinical trials. AEs of interest included overall infections, laboratory abnormalities and AEs associated with influenza vaccination. Pregnancy outcome data were collected from the Adalimumab Pregnancy Registry. Serious infections

EvidenceUpdates2016

54. Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants

Adalimumab (Humira) and plaque psoriasis in children: no better than other immunosuppressants Prescrire IN ENGLISH - Spotlight ''In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants'', 1 July 2016 {1} {1} {1} | | > > > In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight In the July issue of Prescrire International - Adalimumab (Humira°) and plaque psoriasis in children: no better than other immunosuppressants FREE DOWNLOAD In a trial in 114 children, the efficacy of adalimumab was not notably different from that of methotrexate, and its adverse effects profile did not appear to be more favourable. Full text

Prescrire2016

56. Adalimumab (Humira) - Treatment of moderate to severe chronic plaque psoriasis

Adalimumab (Humira) - Treatment of moderate to severe chronic plaque psoriasis Published 11 July 2016 Statement of Advice: adalimumab (Humira ® ) Pre-filled Pen, Pre-filled Syringe and Vial (No: 1173/16) AbbVie Limited 10 June 2016 ADVICE: in the absence of a submission from the holder of the marketing authorisation adalimumab (Humira ® ) is not recommended for use within NHS Scotland. Indication under review: Treatment of moderate to severe chronic plaque psoriasis in adult patients who (...) are candidates for systemic therapy. (This licence extension relates to previous SMC advice (468/08). SMC has previously accepted adalimumab for restricted use for the treatment of chronic plaque psoriasis in adult patients who failed to respond to or have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or PUVA. It is restricted to patients with severe disease as defined by a total Psoriasis Area Severity Index score of =10 and a Dermatology Life Quality

Scottish Medicines Consortium2016

57. Adalimumab (Humira) for uveitis in paediatric patients - second line

Adalimumab (Humira) for uveitis in paediatric patients - second line Adalimumab (Humira) for uveitis in paediatric patients – second line Adalimumab (Humira) for uveitis in paediatric patients – second line NIHR HSRIC Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Adalimumab (Humira) for uveitis in paediatric patients – second line. Birmingham: NIHR (...) Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2016 Authors' conclusions Uveitis affects the lining of the eye. It is an inflammation that can lead to eye pain, eye redness, headaches, and visual problems that can become permanent. In many cases the cause of uveitis is unknown, but it is much more common in patients who are affected by a form of childhood arthritis called juvenile idiopathic arthritis (JIA). Adalimumab is a drug that is already used to treat JIA

Health Technology Assessment (HTA) Database.2016

58. Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model

Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy (including a review of TA140 and TA262): clinical effectiveness systematic review and economic model Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display, please try

NIHR HTA programme2016

59. Adalimumab (Humira) - treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Adalimumab (Humira) - treatment of active moderate to severe hidradenitis suppurativa (HS) (acne inversa)

Scottish Medicines Consortium2016

60. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin

Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifyin Journals Library Journals Library An error has occurred in processing the XML document An error has occurred in processing the XML document An error has occurred in processing the XML document An error occurred retrieving content to display

NIHR HTA programme2016